Compare POWWP & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWWP | XOMAP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 81 | 13 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | POWWP | XOMAP |
|---|---|---|
| Price | $24.20 | $25.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.6K | 926.0 |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.50 | $24.96 |
| 52 Week High | $24.75 | $27.11 |
| Indicator | POWWP | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 36.73 |
| Support Level | $23.86 | $25.54 |
| Resistance Level | $24.42 | $26.25 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 52.55 | 10.36 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.